5.710USDMkt Cap: 35.33M USDP/E: —Last update: 2026-05-21
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap35.33M USD
Enterprise Value-15.22M USD
Revenue (TTM)4.71M USD
Gross Profit-64.75M USD
Net Income (TTM)-24.19M USD
Revenue/Share0.4530 USD
Last Price5.710 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees82
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS01626L1052
Valuation
P/E (Trailing)—
P/E (Forward)-1.36
PEG—
EV/EBITDA0.16
EV/Revenue-3.24
P/S7.51
P/B1.11
EPS (TTM)-9.78
EPS (Forward)-4.19
52W Range
5.52061% of range5.830
52W High5.830 USD
52W Low5.520 USD
Profitability
Gross Margin0.00%
Oper. Margin-951.55%
EBITDA Margin0.00%
Profit Margin-1106.72%
ROE-45.18%
ROA-27.33%
Growth
Revenue Growth810.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-82.50M USD
CapEx (TTM)437.00K USD
FCF Margin-1048.68%
FCF Yield-139.64%
Net Debt-50.56M USD
Net Debt/EBITDA0.53
Balance Sheet
Debt/Equity0.10
Current Ratio2.56
Quick Ratio2.35
Book Value/Sh5.137 USD
Cash/Share8.873 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:25
Split DateAug 19, 2024
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)65.80 USD
Target Range20.00 USD – 175.00 USD
# Analysts5
Ownership
Shares Out.5.39M
Float3.64M
Insiders10.30%
Institutions55.08%
Short Interest
Short Ratio1.3d
Short % Float9.33%
Short % Out.7.91%
Shares Short489.63K
Short (prev mo.)306.18K
Technical
SMA 506.846 (-16.6%)
SMA 2008.428 (-32.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)84.82K
Avg Vol (10d)155.99K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—